{"id":"naftidrofuryl-oxalate","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":[],"aliases":["naftidrofuryl","Praxilene","naftidrofuryl hydrogen oxalate"],"patents":[],"pricing":[],"allNames":"praxilene","offLabel":[],"timeline":[],"aiSummary":"Praxilene is a small molecule with the synonyms DROSUNAL, DUBIMAX, GEVATRAN, NAFTIDROFURILO, NAFTIDROFURYL, and NAFTIDROFURYL.","brandName":"Praxilene","companyId":"merck-serono","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 2A","novelty":"","modality":"Small molecule","drugClass":"5-HT2 receptor antagonist, Peripheral vasodilator","explanation":"Naftidrofuryl oxalate acts primarily as a selective 5-HT2 (serotonin type 2) receptor antagonist. By blocking 5-HT2 receptors on vascular smooth muscle, it prevents serotonin-mediated vasoconstriction and platelet aggregation, thereby improving blood flow in peripheral arteries. Additionally, it enhances cellular metabolism in ischaemic tissues by promoting aerobic glycolysis and reducing lactate accumulation. This dual mechanism — vasodilation plus metabolic improvement — makes it useful in peripheral arterial disease, particularly intermittent claudication. It is one of the few oral vasodilators recommended by NICE for peripheral vascular disease.","oneSentence":"A 5-HT2 receptor antagonist that improves peripheral blood flow and cellular metabolism by blocking serotonin-mediated vasoconstriction and enhancing aerobic metabolism in ischaemic tissues.","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Merck Serono (originally Lipha)","competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"naftidrofuryl oxalate","indications":{"approved":[{"name":"Cerebrovascular disease","diseaseId":"cerebrovascular-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic Occlusive Peripheral Arterial Disease","diseaseId":"chronic-occlusive-peripheral-arterial-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Three times daily","formulation":"Capsule"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":["LS-121"],"ownershipHistory":[],"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":"France","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}